Gilead Sciences, Inc. · GILD · FY2025 Q3 · Calendar Q4 2025

Gilead: HIV growth and Yeztugo momentum support a broader pipeline

The latest analysis supports a cautiously constructive view of Gilead’s growth setup: resilient HIV demand, early Yeztugo coverage and Livdelzi momentum are tangible supports, while policy headwinds and execution-dependent pipeline opportunities keep the longer-term case conditional.

Why did GILD rise 1.1% after beating EPS estimates in FY2025 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNASDAQHealthcare $179.47B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.47 Consensus $2.13
EPS surprise +16.0% Reported versus consensus
Reported revenue $7.77B Consensus $7.45B
Revenue surprise +4.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move +1.1% Event window
SPY move +0.3% Same window
Abnormal move +0.8% Stock minus SPY
Volume 1.5× Versus trailing sessions
Subsequent drift +3.8% Up to 20 sessions
GILDSPY benchmark

Ask FN2 about GILD FY2025 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Relative to the prior-quarter analysis, the current analysis adds 75% Yeztugo payer coverage, more explicit 2026 launch and regulatory milestones, and a quantified Medicare Part D headwind. The underlying narrative remains constructive, but uptake, formulary and execution risks remain central.

Guidance delta

Management raised full-year HIV revenue growth guidance to approximately 5%, despite a stated $900 million Medicare Part D redesign headwind.

Key takeaways

  • Yeztugo reached 75% payer coverage three months ahead of schedule, supporting the company’s stated 2026 growth outlook.
  • HIV franchise momentum remained the central growth driver, while Livdelzi surpassed $100 million in quarterly sales.
  • Pipeline milestones in bulevirtide, Trodelvy and ARTISTRY add potential catalysts, but depend on regulatory and launch execution.
  • The quarter extended the prior period’s constructive setup: strong Yeztugo rollout and raised HIV expectations, with policy and uptake risks still present.

Management priorities

  • Expand Yeztugo payer coverage and manage launch inventory.
  • Advance ARTISTRY and cell-therapy programs.
  • Pursue regulatory and commercial progress for bulevirtide and first-line Trodelvy.
  • Maintain expense discipline while investing in the pipeline.

Follow GILD with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
GILD EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q2 '24 estimate $1.61 Q2 '24 actual $2.01, beat Q3 '24 estimate $1.53 Q3 '24 actual $2.02, beat Q2 '25 estimate $1.96 Q2 '25 actual $2.01, beat Q3 '25 estimate $2.13 Q3 '25 actual $2.47, beat Q4 '25 estimate $1.81 Q4 '25 actual $1.86, beat Q1 '26 estimate $1.91 Q1 '26 actual $2.03, beat Q2 '26 estimate $-7.25 Q2 '26 actual $-6.75, beat Q3 '26 estimate $2.19 Q3 '26 actual $2.55, beat Q4 '26 estimate $2.25 Q1 '27 estimate $2.12
Show 2 more >

Analyst Consensus ?

ConsensusBuy58 ratings
Bullish3967.3%
Neutral1831.0%
Bearish11.7%

Analyst 52W Price Targets

$166.43Current
$54Low
$128.81Average
$196High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 30, 2026
UBS Buy BuyMaintainOct 30, 2026
Truist Securities Buy BuyMaintainOct 30, 2026
TD Cowen Buy BuyMaintainOct 30, 2026
Scotiabank Sector Outperform Sector OutperformMaintainOct 30, 2026
Show 53 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $166.43. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
TD CowenTyler Van Buren$175$168.77 +5.1%Nov 18, 2026
Argus ResearchJasper Hellweg$190$169.05 +14.2%Nov 12, 2026
JefferiesAkash Tewari$196$167.47 +17.8%Nov 4, 2026
BernsteinCourtney Breen$175$167.33 +5.1%Nov 2, 2026
UBSMichael Yee$195$170.95 +17.2%Oct 30, 2026
See 112 more

Track every rating change on GILD the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread.…

Historical context

All GILD earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the GILD recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-05T04:00:42.975890+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-05T04:00:42.972842+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-05. For educational purposes only; not investment advice.